- Home
- NMG vs NMRA Comparison
NMG vs NMRA Comparison
Compare NMG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMG | NMRA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.4M | 554.0M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NMG | NMRA |
|---|---|---|
| Price | $1.80 | $1.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $5.75 | ★ $7.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.72 |
| 52 Week High | $6.06 | $3.65 |
Technical Indicators
Market Signals| Indicator | NMG | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 37.66 |
| Support Level | N/A | $1.67 |
| Resistance Level | $2.03 | $1.95 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.17 | 15.38 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.